1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNCI Cancer Biomarkers Research is sponsored by National Cancer Institute (NCI). Supports research on cancer biomarkers for diagnosis and treatment.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Biomarkers and Cancer Epidemiology | EGRP/DCCPS/NCI/NIH Biomarkers and Cancer Epidemiology Research Related NIH Research Resources Related EGRP Workshops and Meetings Have questions about this topic or need additional assistance? Andrea Burnett-Hartman, PhD, MPH Program Director, Clinical and Translational Epidemiology Branch andrea. burnett-hartman@nih.
gov Biomarkers for early detection/screening of cancer Danielle Carrick, PhD, MHS Program Director, Genomic Epidemiology Branch Biomarkers of nutrition, early life exposures Program Director, Environmental Epidemiology Branch Multi-omics biomarkers for risk assessment and survival Branch Chief, Methods and Technologies Branch Assessment and validation of digital biomarkers (including physical activity, sedentary behavior, and sleep) Program Director, Risk Factor Assessment Branch A biomarker may be a marker of exposure to a substance, its metabolism, or an integration of exposure and metabolism.
Biomarkers may also reflect host characteristics. Digital biomarkers are physiological and behavioral measures derived from digital technology that explain or predict health outcomes. Because biomarkers can be related to risk of disease or monitoring for disease recurrence or progression, they are important in cancer control research.
To be useful in cancer epidemiology, applications of biomarkers should reduce misclassification of exposures and disease, enhance detection of exposure-disease associations, predict disease occurrence or outcomes, predict response to treatments, or increase opportunities for intervention.
NCI’s Epidemiology and Genomics Research Program (EGRP) is interested in the discovery of novel biomarkers as well as understanding how biomarkers can be used in risk factor assessment, early detection/screening of cancer, surveillance for cancer recurrence, predicting treatment response, disease stratification, identifying environmental exposures that may lead to cancer, and as markers of nutrition that either promote or protect against cancer.
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development - expires June 23, 2026 PAR-25-170 (UG3/UH3, Clinical Trial Optional) Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants - expires October 15, 2026 PAR-24-304 (R01, Clinical Trial Not Allowed) Assay Validation of High Quality Markers for Clinical Studies in Cancer - expires October 15, 2026 PAR-25-074 (UH2/UH3, Clinical Trial Not Allowed) PAR-25-075 (UH3, Clinical Trials Not Allowed) EGRP also encourages investigator-initiated grant applications on topics related to biomarkers and cancer epidemiology.
Related NIH Research Resources Biospecimen Resources for Population Scientists A list of links to biospecimen resources that may be of interest to cancer epidemiologists, including policies and best practices for biospecimen research and potential sources of biospecimens.
Cancer Screening Research Network (CSRN) This NCI-supported network conducts rigorous, multi-center cancer screening trials with large populations in a variety of health care settings with the ultimate goal of reducing cancer-related illnesses and deaths.
The CSRN will launch a pilot study in 2025, called the Vanguard Study, to address the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials (RCTs).
Early Detection Research Network (EDRN) NCI’s Early Detection Research Network (EDRN), brings together dozens of institutions to help accelerate the translation of biomarker information into clinical applications and to evaluate new ways of testing cancer in its earliest stages and for cancer risk.
National Institute of Environmental Health Science (NIEHS) Health Topics: Biomarkers This compilation of resources includes studies, clinical trials, educational materials, NIEHS initiatives, and general information related to biomarkers. Last Updated: 03 Sep, 2025
According to the current listing, eligibility includes: Universities, Nonprofits, State/local governments. Confirm the full requirements in the official notice before applying.
NCI Cancer Biomarkers Research is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article